What Is DXCM Fair Value?
Dexcom (DXCM) fair value estimate using multiple valuation models, updated daily.
As of October 14, 2026, Dexcom (DXCM) has a composite fair value estimate of $70.23 based on four valuation models: DCF (41% weight), Graham Number (29% weight), PEG (29% weight), and DDM (0% weight). The current market price is $85.06, suggesting the stock is overvalued by 17.4%.
Data as of October 14, 2026 (today)
Composite Fair Value
Overvalued3 of 4 models$70.23
vs. current price of $85.06(-17.4%)
How Is DXCM Fair Value Calculated?
Four independent models estimate what DXCM is worth. Each uses different inputs and assumptions. The composite blends them by weight.
DXCM Intrinsic Value
Forward-looking models based on future cash flows
DCF (Discounted Cash Flow)
41% weightEstimates how much cash the company will generate over the next 10 years, then calculates what all that future cash is worth in today's dollars. Includes a 15% safety cushion. Try the standalone DCF calculator →
$96.44
+13.4%Fair Value
Inputs used
DDM (Dividend Discount Model)
0% weightIf a company pays you dividends, this model asks: how much are all those future dividend payments worth today? Only works for stocks that pay dividends. Try the intrinsic value calculator →
N/A
This stock does not pay a dividend, so the DDM cannot be applied. The composite adjusts by redistributing this weight to the other models.
DXCM Fair Value
Current fundamentals: earnings, assets, and growth rate
Graham Number (Value Investing)
29% weightCreated by legendary investor Benjamin Graham. It looks at two things: how much the company earns (EPS) and what its assets are worth (Book Value), then calculates the maximum price a careful investor should pay. Try the fair value calculator →
$20.40
-76.0%Overvalued
Inputs used
PEG (Price/Earnings to Growth)
29% weightChecks if you're paying a fair price for the company's growth. A fast-growing company deserves a higher price than a slow one. This model finds the right price based on how fast earnings are growing.
$59.53
-30.0%Overvalued
Inputs used
What If You Change the Assumptions?
Drag the sliders to test different scenarios. Tap the ? buttons to learn what each input means.
Your DCF Fair Value
Current price $85.06 is 13.4% below this estimate
View 10-year cash flow projections
| Year | Projected FCF (Free Cash Flow) | Present Value |
|---|---|---|
| Year 1 | $1.25B | $1.11B |
| Year 2 | $1.53B | $1.21B |
| Year 3 | $1.87B | $1.32B |
| Year 4 | $2.29B | $1.44B |
| Year 5 | $2.80B | $1.57B |
| Year 6 | $3.43B | $1.71B |
| Year 7 | $4.19B | $1.87B |
| Year 8 | $5.13B | $2.03B |
| Year 9 | $6.28B | $2.22B |
| Year 10 | $7.68B | $2.42B |
| Terminal Value | $80.64B | $25.36B |
What Are DXCM's Key Financial Metrics?
Earnings & Growth
Current Price
$85.06
EPS (TTM)
$2.52
Forward P/E
27.2
Profit Margin
20.1%
Cash & Balance Sheet
Free Cash Flow
1B
EBITDA
1.4B
Book Value
$6.95
Total Debt
1.4B
What Do Analysts Say About DXCM?
Low
$79.00
Average
$96.46
High
$115.00
Upside
+13.4%
DXCM Fair Value FAQ
What is the fair value of DXCM?
Based on our composite model (DCF 35%, Graham 25%, PEG 25%, DDM 15%), DXCM's estimated fair value is $70.23. The stock is currently trading at $85.06, which makes it overvalued by our analysis.
How is DXCM's fair value calculated?
We use four valuation methods: Discounted Cash Flow (DCF), Graham Number, PEG-based Fair Value, and Dividend Discount Model (for dividend-paying stocks). The composite score weights DCF at 35%, Graham and PEG at 25% each, and DDM at 15%. When a model can't be applied, its weight is redistributed proportionally.
Is DXCM overvalued or undervalued?
Based on our analysis, DXCM is overvalued. The current price of $85.06 is 17.4% above our estimated fair value of $70.23.
What do Wall Street analysts say about DXCM?
26 analysts cover Dexcom with a consensus rating of "Strong Buy." The average price target is $96.46, ranging from $79.00 to $115.00. This implies 13.4% upside from the current price.